Cochrane Nordic and HPV vaccine safety



Cochrane Nordic, (and associates), has forwarded a complaint to the European Medicines Agency (EMA) over maladministration at the EMA in regards to the safety of HPV vaccines.

Cochrane Nordic’s corrrespondence with the EMA is accessible on this webpage:

I am alerting Cochrane Nordic and the medical journal The BMJ to matters relevant to the safety of human papillomavirus (HPV) vaccines, e.g.

  • the lack of evidence supporting multiple HPV vaccine doses;
  • the lack of evidence for prevention of cancer; 
  • the lack of scientific knowledge about HPV vaccination, i.e. scientists such as Professor Diane Harper admit “the mechanism of immunogenicity from a scientific perspective is poorly understood”;
  • the novel turbo-charged aluminium adjuvants in the VLP HPV vaccine products, which are reported to induce unnaturally high antibody titres, many fold higher than natural HPV infection;
  • the potential for a continuous shift in HPV types (‘type replacement’) as a result of vaccination, and the uncertainties this brings;
  • fear-mongering about the risks of HPV and misleading information; 
  • political interference in the implementation of HPV vaccination, e.g. in Australia, which had a domino effect in fast-tracking HPV vaccination around the world; 
  • the lack of independent and objective evaluation of HPV vaccination; and
  • the lack of ‘informed consent’ before HPV vaccination.

I submitted comments on these matters on Dr Richard Lehman’s 5 December 2016 BMJ blog.  Only one of my comments was published after approval by The BMJ’s lawyer, the rest have been censored pending an investigation into HPV vaccination by The BMJ’s Associate Editor Dr Peter Doshi, as advised to me personally by Dr Fiona Godlee, Editor in Chief of The BMJ (15 Feb 2017).  For information, here is a hyperlink to the comments I submitted to The BMJ:  E Hart unpublished comments re HPV vax on Richard Lehman’s BMJ Blog

My correspondence to Cochrane Nordic and The BMJ can be accessed via the following hyperlinks, see below starting from October 2016 – this matter is ongoing:


1 thought on “Cochrane Nordic and HPV vaccine safety

  1. Pingback: Vaccine safety and aluminium – a challenge to The Cochrane Collaboration | OVER-VACCINATION

Comments are closed.